Valemetostat
Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Other/Multi
Breast Cancer
Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
Wróbel A, Vandenberghe M, Scott M, et al.
Diagn Pathol. 2025 Apr;20(1):35. doi: 10.1186/s13000-025-01624-3.
Other/Multi
Breast Cancer
Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: An observational cohort study
Lam C, Varghese D, Collins J, et al.
Oncologist. 2025 Apr;30(4):oyae280. doi: 10.1093/oncolo/oyae280.
Edoxaban
Cardiovascular - AF
Real-world evidence comparing oral anticoagulants for NVAF in Europe: A systematic review and network meta-analysis
Cichewicz A, Jawla S, Zuchinali P, et al.
Future Cardiology, 21(6), 371–390. https://doi.org/10.1080/14796678.2025.2484119
Other/Multi
Breast Cancer
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: A US real-world cohort study
Modi S, Zhang S, Byng D, et al.
Breast Cancer Res Treat. 2025 Jun;211(2):351-362. doi: 10.1007/s10549-025-07649-y.
Edoxaban
Cardiovascular - AF
Edoxaban treatment in routine clinical practice is highly concordant with the 2020 European Society of Cardiology atrial fibrillation guidelines: Results from the noninterventional Global ETNA-AF programme
Morrone D, Dinshaw L, de Souza JAG, et al.
Eur Heart J Open. 2025 Mar;5(2):oeaf004. doi: 10.1093/ehjopen/oeaf004.
T-DXd
Breast Cancer
A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low breast cancer in Taiwan
Lee K-T, Huang P-H, Hsu C-Y, et al.
Cancer Treat Res Commun. 2025 Mar;43:100893. doi: 10.1016/j.ctarc.2025.100893.
Quizartinib
Hematology
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial
Schlenk RF, Montesinos P, Kim H-J, , et al.
Haematologica. 2025;110(9):2024-2039. doi: 10.3324/haematol.2024.286623
Dato-DXd
Breast Cancer
Lung Cancer
Other/Multi
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis
Meric-Bernstam F, Bardia A, Bossi P, et al.
Oncologist. 2025 Mar;30(3):oyaf031. doi: 10.1093/oncolo/oyaf031.
Dato-DXd
Lung Cancer
Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study
Ahn M-J, Tanaka K, Paz-Ares L, et al.
J Clin Oncol. 2025;43(3):260-272. doi: 10.1200/JCO-24-01544.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below